# EDGAR Filing Document

**Accession Number:** 0000756913
**File Stem:** 0001193125-25-217449
**Filing Date:** 2025-9
**Character Count:** 6009
**Document Hash:** 71a999d4b29c5b46ebcf3952bf7b53ba
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001193125-25-217449.hdr.sgml**: 20250925

**ACCESSION NUMBER**: 0001193125-25-217449

**CONFORMED SUBMISSION TYPE**: 497K

**PUBLIC DOCUMENT COUNT**: 2

**FILED AS OF DATE**: 20250925

**DATE AS OF CHANGE**: 20250925

**EFFECTIVENESS DATE**: 20250925

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** JOHN HANCOCK VARIABLE INSURANCE TRUST
- **CENTRAL INDEX KEY:** 0000756913

**ORGANIZATION NAME:**
- **EIN:** 000000000
- **STATE OF INCORPORATION:** MA
- **FISCAL YEAR END:** 0630

**FILING VALUES:**
- **FORM TYPE:** 497K
- **SEC ACT:** 1933 Act
- **SEC FILE NUMBER:** 002-94157
- **FILM NUMBER:** 251343806

**BUSINESS ADDRESS:**
- **STREET 1:** C/O JOHN HANCOCK FUNDS
- **STREET 2:** 200 BERKELEY STREET
- **CITY:** BOSTON
- **STATE:** MA
- **ZIP:** 02116
- **BUSINESS PHONE:** 617-663-3000

**MAIL ADDRESS:**
- **STREET 1:** C/O JOHN HANCOCK FUNDS
- **STREET 2:** 200 BERKELEY STREET
- **CITY:** BOSTON
- **STATE:** MA
- **ZIP:** 02116

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** JOHN HANCOCK TRUST
- **DATE OF NAME CHANGE:** 20050124

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** MANUFACTURERS INVESTMENT TRUST
- **DATE OF NAME CHANGE:** 19971022

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** NASL SERIES FUND INC
- **DATE OF NAME CHANGE:** 19881030

## Series and Classes Contracts Data

### Blue Chip Growth Trust (Series ID: S000008217)

| Class ID   | Class Name   | Ticker Symbol   |
|:---|:---|:---|
| C000022354 | NAV          | JAEDX           |
| C000022355 | Series I     | JADZX           |
| C000022356 | Series II    | JADYX           |

![](g69969jhim_fcv.jpg)

Prospectus Supplement

**John Hancock Variable Insurance Trust** <br>**Blue Chip Growth Trust (the fund)**

**Supplement dated September 25, 2025 to the current Summary Prospectus, as may be supplemented (the Summary Prospectus)**

At its meeting held on September 23-25, 2025, the Trust's Board of Trustees approved a reduction in the fund's management fee to be retroactively effective as of June 1, 2025 (the Effective Date). As a result, the information in the "Annual fund operating expenses" table and the "Expense example" table for the fund is amended and restated as follows to reflect the fund's revised management fee as of the Effective Date:

---

| | | | |
|:---|:---|:---|:---|
| **Annual fund operating expenses (%)** (expenses that you pay each year as a percentage of the value of your investment) | **Series I** | **Series II** | **Series NAV** |
| Management fee | 0.71 <br><sup>1</sup><br>| 0.71 <br><sup>1</sup><br>| 0.71 <br><sup>1</sup><br>|
| Distribution and service (Rule 12b-1) fees | 0.05 | 0.25 | 0.00 |
| Other expenses | 0.04 | 0.04 | 0.04 |
| **Total annual fund operating expenses** | **0.80** | **1.00** | **0.75** |
| Contractual expense reimbursement | -0.01 <br><sup>2</sup><br>| -0.01 <br><sup>2</sup><br>| -0.01 <br><sup>2</sup><br>|
| **Total annual fund operating expenses after expense reimbursements** | **0.79** | **0.99** | **0.74** |

---

**1**

"Management fee" has been restated to reflect the contractual management fee schedule effective June 1, 2025.

**2**

The advisor contractually agrees to waive a portion of its management fee and/or reimburse expenses for the fund and certain other John Hancock funds according to an asset level breakpoint schedule that is based on the aggregate net assets of all the funds participating in the waiver or reimbursement, including the fund (the participating portfolios). This waiver equals, on an annualized basis, 0.0100% of that portion of the aggregate net assets of all the participating portfolios that exceeds $75 billion but is less than or equal to $125 billion; 0.0125% of that portion of the aggregate net assets of all the participating portfolios that exceeds $125 billion but is less than or equal to $150 billion; 0.0150% of that portion of the aggregate net assets of all the participating portfolios that exceeds $150 billion but is less than or equal to $175 billion; 0.0175% of that portion of the aggregate net assets of all the participating portfolios that exceeds $175 billion but is less than or equal to $200 billion; 0.0200% of that portion of the aggregate net assets of all the participating portfolios that exceeds $200 billion but is less than or equal to $225 billion; and 0.0225% of that portion of the aggregate net assets of all the participating portfolios that exceeds $225 billion. The amount of the reimbursement is calculated daily and allocated among all the participating portfolios in proportion to the daily net assets of each participating portfolio. During its most recent fiscal year, the fund's reimbursement amounted to 0.01% of the fund's average daily net assets. This agreement expires on July 31, 2027, unless renewed by mutual agreement of the fund and the advisor based upon a determination that this is appropriate under the circumstances at that time.

**Expense example**

------

The examples are intended to help you compare the cost of investing in the fund with the cost of investing in other mutual funds. The examples assume that $10,000 is invested in the fund for the periods indicated and then all shares are redeemed at the end of those periods. The examples also assume that the investment has a 5% return each year and that the fund's operating expenses remain the same. The expense example does not reflect fees and expenses of any variable insurance contract that may use the fund as its underlying investment option and would be higher if they did. Although your actual costs may be higher or lower, based on these assumptions your costs would be:

---

| | | | |
|:---|:---|:---|:---|
| **Expenses ($)** | **Series I** | **Series II** | **Series NAV** |
| 1 year | 81 | 101 | 76 |
| 3 years | 254 | 317 | 239 |
| 5 years | 443 | 551 | 416 |
| 10 years | 989 | 1224 | 929 |

---

*You should read this supplement in conjunction with the Summary Prospectus and retain it for your future reference.*

------